Utility of the Age Discrepancy between Frailty-Based Biological Age and Expected Life Age in Patients with Urological Cancers

Togashi, Kyo; Sato, Osamu; Okita, Kazutaka; Fujita, Naoki; Tanaka, Toshikazu; Noro, Daisuke; Horiguchi, Hirotaka; Uemura, Nozomi; Iwane, Takuro; Okamoto, Teppei; Yamamoto, Hayato; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Οhyama, Chikara

doi:10.3390/cancers14246229

Cited by 4 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our previous studies have suggested that the degree of frailty increases at age 80 or older, which may be useful as a convenient cutoff for Japanese patients. 14…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Trends in the age of hospitalized patients with urological cancers: A 17‐year experience

et al. 2023

Self Cite

View full text Add to dashboard Cite

Objectives To investigate the impact of global aging on the trends in the age of hospitalized patients with a urological cancer diagnosis. Methods We retrospectively evaluated a cumulative total of 10 652 cases of referred patients (n = 6637) with a urological disease who were hospitalized in our institution between January 2005 and December 2021. We compared age and the proportion of patients aged ≥80 years among patients who were hospitalized in the urological ward between the period of 2005–2013 and that of 2014–2021. Results We identified 8168 hospitalized patients with urological cancer. The median age was significantly increased in patients with urological cancer between the periods of 2005–2013 and 2014–2021. The proportion of hospitalized patients with urological cancer aged ≥80 years was significantly increased between the periods of 2005–2013 (9.3%) and 2014–2021 (13.8%). The median ages of the patients with urothelial cancer (UC) and renal cell carcinoma (RCC), but not the median age of those with prostate cancer (PC), were significantly increased between the study periods. The proportion of hospitalized patients with UC, but not the proportions of those with PC and RCC, aged ≥80 years was significantly increased between the study periods. Conclusions The age of patients with urological cancer who were hospitalized in the urological ward and the proportion of patients with UC aged ≥80 years significantly increased over the entire study period.

show abstract

“…Our previous studies have suggested that the degree of frailty increases at age 80 or older, which may be useful as a convenient cutoff for Japanese patients. 14…”

Section: Discussionmentioning

confidence: 99%

“…We selected the age of 80 as a threshold because it is an important cutoff value for determining the indication for surgery and the intensity of treatment. Our previous studies have suggested that the degree of frailty increases at age 80 or older, which may be useful as a convenient cutoff for Japanese patients 14 …”

Section: Methodsmentioning

confidence: 99%

Trends in the age of hospitalized patients with urological cancers: A 17‐year experience

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…Within the context of onconephrology, there have been recommendations to utilize a ‘simple value score’ based on age to determine the extent of frailty. A recently published study by Togashi and colleagues [ 109 ] investigated frailty-based biological ages using frailty-discriminant scores (FDS) and examined the effect of biological–expected life age discrepancy on the prognosis of patients with urological cancers. The FDS is a comprehensive frailty assessment tool including eGFR as a frailty parameter [ 110 ].…”

Section: Recommendations For a Summarized Frailty Assessment Tool In ...mentioning

confidence: 99%

Is It Time to Integrate Frailty Assessment in Onconephrology?

Chinnadurai

Walker

et al. 2023

Cancers

View full text Add to dashboard Cite

Onconephrology has emerged as a novel sub-specialty of nephrology dedicated to the intersection between the kidney and cancer. This intersection is broad and includes a number of important areas of focus, including concurrent chronic kidney disease (CKD) and cancer, acute kidney complications of cancer, and cancer-treatment-induced nephrotoxicity. The importance of onconephrology is even more evident when considering the global growth in the population of older adults, many of whom are living with some degree of frailty. Furthermore, a considerable proportion of older adults have CKD (some of whom eventually progress to kidney failure) and are at high risk of developing solid tumour and hematologic malignancies. Specific to kidney disease, the association between frailty status and kidney disease has been explored in depth, and tools to capture frailty can be used to guide the management and prognostication of older adults living with kidney failure. Whilst there is emerging data regarding the assessment and impact of frailty in onconephrology, there remains a relative paucity of knowledge within this topic. In this article, we evaluate the definition and operationalization of frailty and discuss the significance of frailty within onconephrology. We review evidence on current approaches to assessing frailty in onconephrology and discuss potential developments and future directions regarding the utilization of frailty in this patient population. A greater awareness of the intersections and interactions between frailty and onconephrology and further efforts to integrate frailty assessment in onconephrology to optimize the delivery of realistic and goal-directed management strategies for patients is needed.

show abstract

Should clinical trials about prostate cancer assess the frailty as an endpoint?

Karahan¹,

Dede

2023

Int Urol Nephrol

View full text Add to dashboard Cite

Utility of the Age Discrepancy between Frailty-Based Biological Age and Expected Life Age in Patients with Urological Cancers

Cited by 4 publications

References 28 publications

Trends in the age of hospitalized patients with urological cancers: A 17‐year experience

Trends in the age of hospitalized patients with urological cancers: A 17‐year experience

Is It Time to Integrate Frailty Assessment in Onconephrology?

Should clinical trials about prostate cancer assess the frailty as an endpoint?

Contact Info

Product

Resources

About